A5062894702- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Cancer therapeutics and mechanisms
- Lung Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Neuroendocrine Tumor Research Advances
- RNA modifications and cancer
- Peptidase Inhibition and Analysis
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Medical Imaging and Pathology Studies
- COVID-19 and healthcare impacts
- Gastric Cancer Management and Outcomes
- Advances in Oncology and Radiotherapy
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- Neutropenia and Cancer Infections
- Cancer Mechanisms and Therapy
- PI3K/AKT/mTOR signaling in cancer
- Cancer, Lipids, and Metabolism
- Cancer Treatment and Pharmacology
- Chronic Lymphocytic Leukemia Research
- Quinazolinone synthesis and applications
- Global Cancer Incidence and Screening
- COVID-19 Clinical Research Studies
AstraZeneca (United States)
2021-2025
Vanderbilt University Medical Center
2015-2024
AstraZeneca (Spain)
2024
Vanderbilt University
2013-2023
Vanderbilt-Ingram Cancer Center
2013-2023
Fondazione IRCCS Istituto Nazionale dei Tumori
2020
Università degli Studi del Piemonte Orientale “Amedeo Avogadro”
2020
Mario Negri Institute for Pharmacological Research
2020
Istituti di Ricovero e Cura a Carattere Scientifico
2020
Humanitas University
2020
Enhancing tumor-specific T-cell immunity by inhibiting programmed death ligand 1 (PD-L1)–programmed (PD-1) signaling has shown promise in the treatment of extensive-stage small-cell lung cancer. Combining checkpoint inhibition with cytotoxic chemotherapy may have a synergistic effect and improve efficacy.
The EGFR T790M mutation is the most common mechanism of drug resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in patients who have lung cancer with an (EGFR-mutated cancer). In preclinical models, inhibitor AZD9291 has been shown be effective against both inhibitor–sensitizing and mutations.
A splice-site mutation that results in a loss of transcription exon 14 the oncogenic driver MET occurs 3 to 4% patients with non-small-cell lung cancer (NSCLC). We evaluated efficacy and safety tepotinib, highly selective inhibitor, this patient population. In open-label, phase 2 study, we administered tepotinib (at dose 500 mg) once daily advanced or metastatic NSCLC confirmed skipping mutation. The primary end point was objective response by independent review among who had undergone at...
IMpower133 (ClinicalTrials.gov identifier: NCT02763579), a randomized, double-blind, phase I/III study, demonstrated that adding atezolizumab (anti-programmed death-ligand 1 [PD-L1]) to carboplatin plus etoposide (CP/ET) for first-line (1L) treatment of extensive-stage small-cell lung cancer (ES-SCLC) resulted in significant improvement overall survival (OS) and progression-free (PFS) versus placebo CP/ET. Updated OS, disease progression patterns, safety, exploratory biomarkers (PD-L1,...
Purpose Patients with extensive-stage disease small-cell lung cancer (SCLC) have poor survival outcomes despite first-line chemotherapy etoposide and platinum. This randomized, double-blind phase III study evaluated the efficacy safety of ipilimumab or placebo plus platinum in patients newly diagnosed SCLC. Methods were randomly assigned at a ratio one to receive (cisplatin carboplatin) 10 mg/kg every 3 weeks for total four doses each phased induction schedule (chemotherapy cycles four;...
These NCCN Guidelines Insights focus on recent updates to the 2015 for Non-Small Cell Lung Cancer (NSCLC). Appropriate targeted therapy is very effective in patients with advanced NSCLC who have specific genetic alterations. Therefore, it important test tumor tissue from determine whether they alterations that make them candidates therapies. describe different testing methods currently available determining 2 most commonly actionable alterations, notably anaplastic lymphoma kinase (ALK) gene...
To evaluate the personal and professional characteristics associated with career satisfaction burnout among US oncologists.Between October 2012 March 2013, American Society of Clinical Oncology conducted a survey oncologists evaluating satisfaction. The sample included equal numbers men women represented all stages.Of 2,998 contacted, 1,490 (49.7%) returned surveys (median age respondents, 52 years; 49.6% women). Among 1,117 (37.3% overall sample) who completed full-length surveys, 377...
Nivolumab monotherapy is approved in the United States for third-line or later metastatic small cell lung cancer based on pooled data from nonrandomized and randomized cohorts of multicenter, open-label, phase 1/2 trial nivolumab ± ipilimumab (CheckMate 032; NCT01928394). We report updated results, including long-term overall survival (OS), cohort.Patients with disease progression after one to two prior chemotherapy regimens were 3:2 3 mg/kg every 2 weeks 1 plus four cycles followed by...
•The primary endpoint of OS with nivolumab versus chemotherapy as second-line treatment SCLC was not met.•Crossing the survival curves indicates higher long-term in a subset patients.•Post hoc analyses suggest patients baseline LDH ≤ ULN and those without liver metastases may benefit from nivolumab.•The safety profile consistent prior studies more favorable than that chemotherapy. BackgroundPatients relapsed small-cell lung cancer (SCLC) have few options dismal survival. Phase I/II data show...
IntroductionOsimertinib is a third-generation EGFR-tyrosine kinase inhibitor (TKI). Durvalumab an anti–programmed death ligand 1 monoclonal antibody. The phase III open-label CAURAL trial (NCT02454933) investigated osimertinib plus durvalumab versus monotherapy in patients with EGFR-TKI sensitizing and EGFR T790M mutation–positive advanced NSCLC disease progression after therapy.MethodsPatients were randomly assigned 1:1 to receive orally administered (80 mg once daily) or without (10 mg/kg...
Abstract Purpose: The evaluation of plasma testing for the EGFR resistance mutation T790M in NSCLC patients has not been broadly explored. We investigated detection activating and mutations matched tumor tissue plasma, mostly from with acquired to first-generation inhibitors. Experimental Design: Samples were obtained two studies, an observational study a phase I trial rociletinib, mutant-selective inhibitor that targets both T790M. Plasma was performed cobas test BEAMing. Results: positive...
Ensartinib, an oral tyrosine kinase inhibitor of anaplastic lymphoma (ALK), has shown systemic and central nervous system efficacy for patients with ALK-positive non-small cell lung cancer (NSCLC).To compare ensartinib crizotinib among advanced NSCLC who had not received prior treatment ALK inhibitor.This open-label, multicenter, randomized, phase 3 trial conducted in 120 centers 21 countries enrolled 290 between July 25, 2016, November 12, 2018. Eligible were 18 years age or older advanced,...
The addition of atezolizumab to carboplatin and etoposide (CP/ET) significantly improved progression-free overall survival for patients with extensive-stage small-cell lung cancer (ES-SCLC) in the IMpower133 study (NCT02763579). We have evaluated adverse events (AEs) patient-reported outcomes assess benefit-risk profile this regimen.Patients received four 21-day cycles CP/ET plus intravenous 1200 mg or placebo (induction phase), followed by (maintenance phase) until progression loss benefit....
Despite initial effectiveness of ALK receptor tyrosine kinase inhibitors (TKIs) in patients with ALK+ NSCLC, therapeutic resistance will ultimately develop. Serial tracking genetic alterations detected circulating tumor DNA (ctDNA) can be an informative strategy to identify response and resistance. This study evaluated the utility analyzing ctDNA as a function ensartinib, potent second-generation TKI.Pre-treatment plasma was collected from 76 NSCLC who were TKI-naive or had received prior...
Purpose To investigate the efficacy and safety of bevacizumab plus cisplatin etoposide in patients with extensive-stage disease, small-cell lung cancer (ED-SCLC). Patients Methods In this phase II trial, 63 were treated 15 mg/kg 60 mg/m 2 120 , which was followed by alone until death or disease progression occurred. The primary end point proportion alive at 6 months without (ie, progression-free survival [PFS]). Secondary points included overall (OS), objective response rate, toxicity....
7525^ Background: Despite initial responses to reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, (erlotinib or gefitinib), all non-small cell lung cancer (NSCLC) patients with EGFR-sensitizing mutations experience disease progression. This "acquired resistance" (AR) is associated a second site exon 20 EGFR T790M mutation (M) in >50% of cases. No therapy, including the anti-EGFR antibody cetuximab plus erlotinib, has proven effective treating AR (Janjigian YY....